毕得医药总经理戴岚拟减持不超0.16%股份

Core Viewpoint - Bid Pharma (688073.SH) announced that its controlling shareholder, actual controller, chairman, and general manager, Dai Lan, plans to reduce his shareholding within three months after the disclosure of the reduction plan, depending on market conditions [1] Summary by Sections - Shareholding Reduction Plan - Dai Lan intends to reduce his holdings through centralized bidding transactions, with a maximum reduction of 148,800 shares, which accounts for 0.16% of the company's total share capital [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1]